Corline Biomedical (Q2 Initial take): Lower sales than expected, but long-term case intact - Redeye
Bildkälla: Stockfoto

Corline Biomedical (Q2 Initial take): Lower sales than expected, but long-term case intact - Redeye

Redeye provides an initial take following the release of Corline’s Q2 2026 report. Sales came in somewhat below our expectations, although we highlight the significant uncertainty surrounding our estimates at this early stage of the Globe launch. We had hoped to see a clearer sequential sales ramp-up; however, our long-term view of the company remains intact. We will shortly release a research update, in which we expect to make some smaller downward adjustments to our short-term sales estimates. Nevertheless, we expect the share to continue offering clear upside potential.

Redeye provides an initial take following the release of Corline’s Q2 2026 report. Sales came in somewhat below our expectations, although we highlight the significant uncertainty surrounding our estimates at this early stage of the Globe launch. We had hoped to see a clearer sequential sales ramp-up; however, our long-term view of the company remains intact. We will shortly release a research update, in which we expect to make some smaller downward adjustments to our short-term sales estimates. Nevertheless, we expect the share to continue offering clear upside potential.
Börsvärldens nyhetsbrev